Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294931 · ClinicalTrials.gov registry record · Phase 2
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00294931 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 50 participants.
The verdict
NCT00294931, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.
Interventions
- DRUG carboplatin
- DRUG bevacizumab
- DRUG irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294931
The ClinicalTrials.gov registry entry for NCT00294931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00294931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294931 about?
NCT00294931 is a clinical study titled "Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer". This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.
What is the current status of trial NCT00294931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00294931?
The interventions under investigation include: carboplatin (DRUG), bevacizumab (DRUG), irinotecan (DRUG).
Who is sponsoring clinical trial NCT00294931?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.